Method and a pharmaceutical composition for the inhibition of angiogenesis
Patent 5135919 Issued on August 4, 1992. Estimated Expiration Date: 
August 4, 2009. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
August 4, 2009. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent References 2803586 2844512 3232833 Pharmaceutical preparations containing cyclodextrin derivatives Patent #: 4727064 InventorsAssigneeApplicationNo. 173305 filed on 03/25/1988US Classes:514/56, Heparin or derivative514/24, S-glycoside514/58, Dextrin or derivative514/475The hetero ring is three-memberedExaminersPrimary: Griffin, Ronald W.Assistant: Webber, Pamela S. Attorney, Agent or FirmInternational ClassesA61K 031/715A61K 031/70 AbstractFumagillin and its salts have an angiogenesis inhibiting activity and are useful for prophylaxis and treatment of diseases induced by abnormally stimulated neovascularization. The invention also provides certain pharmaceutical compositions comprising fumagillin or its salt, and an agent which potentiates angiogenesis inhibition such as heparin and sulfated cyclodextrins such as beta-cyclodextrin tetradecasulfate.Other References
| |
